Lantheus to Present New Radiodiagnostic Data at SNMMI Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2026
0mins
Source: Newsfilter
- New Data Presentation: Lantheus Holdings will showcase new radiodiagnostic data at the 2026 Society of Nuclear Medicine and Medical Imaging Annual Meeting from June 1 to June 2 in Los Angeles, aimed at enhancing clinicians' ability to identify and manage diseases.
- Poster Presentation: On June 1, Neal Shore will present on the impact of PSMA-PET with Piflufolastat F18 on prostate cancer management for patients with low or ultra-low PSA levels, emphasizing the significance of this technology in precision medicine.
- Oral Presentation: On June 2, Sangwon Han will discuss the diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis in symptomatic patients, showcasing phase 2 study results that may provide new diagnostic tools for clinical practice.
- Company Background: Lantheus has been focused on radiopharmaceutical development for 70 years, committed to leveraging innovative science to help clinicians better find, fight, and follow diseases, ultimately improving patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LNTH
Wall Street analysts forecast LNTH stock price to fall
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 99.620
Low
70.00
Averages
82.17
High
105.00
Current: 99.620
Low
70.00
Averages
82.17
High
105.00
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lantheus to Speak at Growth Stock Conference
- Conference Participation: John Wiggins, Vice President of External Manufacturing at Lantheus Holdings, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference on June 3, showcasing the company's leadership in the radiopharmaceutical sector.
- Live Webcast: The live session is scheduled to begin at 12:10 p.m. ET, allowing investors to access the presentation through the Investors section of the company's website, ensuring transparent communication of key information.
- Replay Availability: A replay of the webcast will be available on the company's website for at least 30 days post-event, providing crucial insights for investors who cannot attend live, thereby enhancing investor relations.
- Company Background: Lantheus has been dedicated to radiopharmaceutical solutions for 70 years, focusing on enabling clinicians to Find, Fight, and Follow disease, ultimately improving patient outcomes.
See More
Lantheus Weighs Sale Following $7 Billion Curium Offer
- Acquisition Proposal: Lantheus Holdings is considering a takeover offer from Curium Pharma valued at approximately $7 billion, indicating strong market interest in its nuclear medicine business and potentially prompting a strategic overhaul.
- Negotiation Progress: The two companies are in discussions about a potential deal that could materialize in weeks, although no final decision has been made, reflecting uncertainty about Lantheus's future in the market.
- Market Reaction: Lantheus shares fell nearly 2% in after-hours trading, yet they have surged 54.8% this year, indicating investor confidence in its long-term growth potential despite short-term volatility.
- Valuation Insight: With a current market capitalization of about $6.15 billion, the acquisition proposal's valuation underscores Lantheus's competitiveness in the radiopharmaceutical sector, potentially attracting further investor interest in its future trajectory.
See More
Lantheus Evaluates Sale After $7 Billion Curium Offer, Stock Rises 7.4%
- Acquisition Talks Progress: Lantheus Holdings (LNTH) surged 7.4% following a takeover offer from Curium, valuing the firm at approximately $7 billion, indicating strong market optimism regarding potential transaction outcomes.
- Strong Market Reaction: Following the Bloomberg report, Lantheus's market cap reached $6.2 billion, with investor interest in the potential deal spiking, reflecting a positive outlook on the company's future business prospects.
- Existing Partnership: Lantheus and Curium have an existing partnership, which lays the groundwork for a potential transaction, suggesting possible synergies in business integration between the two firms.
- Stable Financial Outlook: Lantheus reiterated its 2026 revenue outlook of $1.4 billion to $1.45 billion, demonstrating robust financial performance during acquisition discussions, which bolsters investor confidence.
See More
Lantheus to Present New Radiodiagnostic Data at SNMMI Annual Meeting
- New Data Presentation: Lantheus Holdings will showcase new radiodiagnostic data at the 2026 Society of Nuclear Medicine and Medical Imaging Annual Meeting from June 1 to June 2 in Los Angeles, aimed at enhancing clinicians' ability to identify and manage diseases.
- Poster Presentation: On June 1, Neal Shore will present on the impact of PSMA-PET with Piflufolastat F18 on prostate cancer management for patients with low or ultra-low PSA levels, emphasizing the significance of this technology in precision medicine.
- Oral Presentation: On June 2, Sangwon Han will discuss the diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis in symptomatic patients, showcasing phase 2 study results that may provide new diagnostic tools for clinical practice.
- Company Background: Lantheus has been focused on radiopharmaceutical development for 70 years, committed to leveraging innovative science to help clinicians better find, fight, and follow diseases, ultimately improving patient outcomes.
See More
Lantheus to Present New Data at ASCO Meeting
- Clinical Research Showcase: Lantheus will present data on LNTH-2403 at the 2026 American Society of Clinical Oncology Annual Meeting, focusing on its safety and preliminary anti-neoplastic activity for relapsed osteosarcoma, potentially offering new treatment options for patients.
- Presentation Schedule: The poster presentation is scheduled for June 1, with poster number 376b, covering pharmacokinetics and radiation dosimetry, which is expected to attract attention from clinicians and researchers alike.
- Real-World Data Analysis: Lantheus will also release findings on the real-world use of piflufolastat F 18 in early-stage prostate cancer, providing valuable data to support clinical practice.
- Company Background: As a leading radiopharmaceutical company, Lantheus has been delivering innovative radiopharmaceutical solutions for 70 years, enabling clinicians to better find, fight, and follow diseases, thereby improving patient outcomes.
See More
Lantheus Holdings Reports Strong Q1 2026 Earnings Call Insights
- Strong Revenue Performance: Lantheus achieved $377.3 million in revenue for Q1 2026, reflecting year-over-year growth primarily driven by solid performances from PYLARIFY, NEURACEQ, and DEFINITY, indicating the company's ability to maintain stability in a competitive market.
- Product Transition Plan: The company plans to transition PYLARIFY directly to PYLARIFY TRUVU starting in Q4 2026, with significant revenue contributions expected in 2027, highlighting strategic decision-making in product innovation and market adaptability.
- Regulatory Milestone: The FDA approved PYLARIFY TRUVU on March 6, which is expected to enhance production capacity and patient coverage, further solidifying Lantheus's market position in the radiotherapeutic sector.
- Full-Year Performance Outlook: Despite a strong Q1, the CFO reiterated the full-year revenue guidance of $1.4 billion to $1.45 billion for 2026, reflecting the company's cautious stance amid competition and the CEO transition period.
See More
Lantheus to Speak at Growth Stock Conference
- Conference Participation: John Wiggins, Vice President of External Manufacturing at Lantheus Holdings, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference on June 3, showcasing the company's leadership in the radiopharmaceutical sector.
- Live Webcast: The live session is scheduled to begin at 12:10 p.m. ET, allowing investors to access the presentation through the Investors section of the company's website, ensuring transparent communication of key information.
- Replay Availability: A replay of the webcast will be available on the company's website for at least 30 days post-event, providing crucial insights for investors who cannot attend live, thereby enhancing investor relations.
- Company Background: Lantheus has been dedicated to radiopharmaceutical solutions for 70 years, focusing on enabling clinicians to Find, Fight, and Follow disease, ultimately improving patient outcomes.
See More
Lantheus Weighs Sale Following $7 Billion Curium Offer
- Acquisition Proposal: Lantheus Holdings is considering a takeover offer from Curium Pharma valued at approximately $7 billion, indicating strong market interest in its nuclear medicine business and potentially prompting a strategic overhaul.
- Negotiation Progress: The two companies are in discussions about a potential deal that could materialize in weeks, although no final decision has been made, reflecting uncertainty about Lantheus's future in the market.
- Market Reaction: Lantheus shares fell nearly 2% in after-hours trading, yet they have surged 54.8% this year, indicating investor confidence in its long-term growth potential despite short-term volatility.
- Valuation Insight: With a current market capitalization of about $6.15 billion, the acquisition proposal's valuation underscores Lantheus's competitiveness in the radiopharmaceutical sector, potentially attracting further investor interest in its future trajectory.
See More
Lantheus Evaluates Sale After $7 Billion Curium Offer, Stock Rises 7.4%
- Acquisition Talks Progress: Lantheus Holdings (LNTH) surged 7.4% following a takeover offer from Curium, valuing the firm at approximately $7 billion, indicating strong market optimism regarding potential transaction outcomes.
- Strong Market Reaction: Following the Bloomberg report, Lantheus's market cap reached $6.2 billion, with investor interest in the potential deal spiking, reflecting a positive outlook on the company's future business prospects.
- Existing Partnership: Lantheus and Curium have an existing partnership, which lays the groundwork for a potential transaction, suggesting possible synergies in business integration between the two firms.
- Stable Financial Outlook: Lantheus reiterated its 2026 revenue outlook of $1.4 billion to $1.45 billion, demonstrating robust financial performance during acquisition discussions, which bolsters investor confidence.
See More
Lantheus to Present New Radiodiagnostic Data at SNMMI Annual Meeting
- New Data Presentation: Lantheus Holdings will showcase new radiodiagnostic data at the 2026 Society of Nuclear Medicine and Medical Imaging Annual Meeting from June 1 to June 2 in Los Angeles, aimed at enhancing clinicians' ability to identify and manage diseases.
- Poster Presentation: On June 1, Neal Shore will present on the impact of PSMA-PET with Piflufolastat F18 on prostate cancer management for patients with low or ultra-low PSA levels, emphasizing the significance of this technology in precision medicine.
- Oral Presentation: On June 2, Sangwon Han will discuss the diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis in symptomatic patients, showcasing phase 2 study results that may provide new diagnostic tools for clinical practice.
- Company Background: Lantheus has been focused on radiopharmaceutical development for 70 years, committed to leveraging innovative science to help clinicians better find, fight, and follow diseases, ultimately improving patient outcomes.
See More
Lantheus to Present New Data at ASCO Meeting
- Clinical Research Showcase: Lantheus will present data on LNTH-2403 at the 2026 American Society of Clinical Oncology Annual Meeting, focusing on its safety and preliminary anti-neoplastic activity for relapsed osteosarcoma, potentially offering new treatment options for patients.
- Presentation Schedule: The poster presentation is scheduled for June 1, with poster number 376b, covering pharmacokinetics and radiation dosimetry, which is expected to attract attention from clinicians and researchers alike.
- Real-World Data Analysis: Lantheus will also release findings on the real-world use of piflufolastat F 18 in early-stage prostate cancer, providing valuable data to support clinical practice.
- Company Background: As a leading radiopharmaceutical company, Lantheus has been delivering innovative radiopharmaceutical solutions for 70 years, enabling clinicians to better find, fight, and follow diseases, thereby improving patient outcomes.
See More
Lantheus Holdings Reports Strong Q1 2026 Earnings Call Insights
- Strong Revenue Performance: Lantheus achieved $377.3 million in revenue for Q1 2026, reflecting year-over-year growth primarily driven by solid performances from PYLARIFY, NEURACEQ, and DEFINITY, indicating the company's ability to maintain stability in a competitive market.
- Product Transition Plan: The company plans to transition PYLARIFY directly to PYLARIFY TRUVU starting in Q4 2026, with significant revenue contributions expected in 2027, highlighting strategic decision-making in product innovation and market adaptability.
- Regulatory Milestone: The FDA approved PYLARIFY TRUVU on March 6, which is expected to enhance production capacity and patient coverage, further solidifying Lantheus's market position in the radiotherapeutic sector.
- Full-Year Performance Outlook: Despite a strong Q1, the CFO reiterated the full-year revenue guidance of $1.4 billion to $1.45 billion for 2026, reflecting the company's cautious stance amid competition and the CEO transition period.
See More
